|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 305.50 SEK | +0.03% |
|
+1.53% | +14.53% |
| Nov. 29 | Di: These seven hard-to-get stocks to buy according to the experts | FW |
| Nov. 25 | Danske Bank Upgrades Sobi to Buy, Lifts PT | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 105B 9.53B 9.08B 8.44B 7.53B 13.4B 807B 14.75B 38.93B 331B 35.79B 34.99B 1,421B | P/E ratio 2024 * |
30.1x | P/E ratio 2025 * | 21.8x |
|---|---|---|---|---|---|
| Enterprise value | 119B 10.82B 10.31B 9.59B 8.56B 15.23B 917B 16.76B 44.22B 376B 40.66B 39.75B 1,614B | EV / Sales 2024 * |
4.68x | EV / Sales 2025 * | 4.04x |
| Free-Float |
51.66% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Swedish Orphan Biovitrum AB
More recommendations
More press releases
More news
| 1 day | +0.99% | ||
| 1 week | +2.28% | ||
| Current month | +0.99% | ||
| 1 month | -7.29% | ||
| 3 months | -3.29% | ||
| 6 months | +8.14% | ||
| Current year | +14.38% |
1 week
299.60
310.40
1 month
286.80336.60
Current year
243.20354.40
1 year
236.40354.40
3 years
169.45354.40
5 years
127.10354.40
10 years
73.10354.40
| Director | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 2017-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 2018-07-19 |
| Chief Tech/Sci/R&D Officer | 53 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 2011-05-04 | |
Annette Clancy
CHM | Chairman | 70 | 2024-01-04 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 2019-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.15% | 228 M€ | +8.22% | ||
| 0.90% | 4 M€ | +19.28% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.99% | +2.28% | +21.87% | +34.77% | 9.53B | ||
| +1.42% | +1.57% | +7.74% | -4.38% | 87.75B | ||
| -0.41% | +1.36% | +36.57% | +8.86% | 49.23B | ||
| +0.32% | +0.95% | +160.14% | +92.30% | 37.02B | ||
| +2.24% | +3.48% | -30.01% | -28.13% | 23.93B | ||
| -1.81% | -0.38% | +35.58% | +9.92% | 14.11B | ||
| -0.60% | -0.30% | +46.91% | -38.24% | 12.61B | ||
| -1.50% | -0.08% | -29.63% | -23.19% | 12.4B | ||
| +7.86% | -8.76% | +265.62% | +410.42% | 11.47B | ||
| +1.19% | +1.64% | -53.76% | -63.73% | 9.79B | ||
| Average | +0.97% | +2.03% | +46.10% | +39.86% | 26.78B | |
| Weighted average by Cap. | +0.86% | +1.72% | +41.61% | +24.56% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 25.44B 2.31B 2.2B 2.05B 1.83B 3.25B 196B 3.58B 9.44B 80.25B 8.68B 8.49B 345B | 27.9B 2.53B 2.41B 2.25B 2B 3.57B 215B 3.92B 10.36B 88B 9.52B 9.31B 378B |
| Net income | 3.5B 318M 303M 282M 251M 447M 26.94B 492M 1.3B 11.04B 1.19B 1.17B 47.42B | 4.85B 440M 420M 390M 348M 620M 37.32B 682M 1.8B 15.29B 1.65B 1.62B 65.69B |
| Net Debt | 14.26B 1.29B 1.23B 1.15B 1.02B 1.82B 110B 2.01B 5.29B 44.97B 4.87B 4.76B 193B | 7.84B 712M 678M 631M 563M 1B 60.33B 1.1B 2.91B 24.72B 2.67B 2.61B 106B |
More financial data
* Estimated data
Employees
1,814
Sector
Pharmaceuticals
Calendar
2024-12-11
- Extraordinary Shareholders Meeting
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-03 | 305.80 kr | +0.13% | 258,321 |
| 24-12-02 | 305.40 kr | +0.99% | 275,304 |
| 24-11-29 | 302.40 kr | -1.11% | 484,057 |
| 24-11-28 | 305.80 kr | -0.65% | 233,791 |
| 24-11-27 | 307.80 kr | +2.19% | 366,202 |
Delayed Quote Nasdaq Stockholm, December 02, 2024 at 12:00 pm EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
305.40SEK
Average target price
360.64SEK
Spread / Average Target
+18.09%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SOBI Stock